Beranda › Kanker Payudara Triple-Negatif › Minnesota › Rochester
Uji klinis Kanker Payudara Triple-Negatif di Rochester, MN
11 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Rochester (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
PRE-ISPY Phase I/II Oncology Platform Program
Menerima pesertaFase 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Menerima peserta
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- Mayo Clinic Rochester, Rochester
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Menerima pesertaFase 2
- Mayo Clinic, Rochester
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Mayo Clinic, Rochester
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Menerima pesertaFase 3
- Mayo Clinic Rochester, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Menerima pesertaFase 1
- Mayo Clinic Rochester, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Menerima pesertaFase 1/2
- Mayo Clinic - Rochester, Rochester
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Menerima pesertaFase 1
- Mayo Clinic Rochester, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Menerima pesertaFase 2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- Mayo Clinic, Rochester
Uji klinis Kanker Payudara Triple-Negatif di kota lain
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Studi lain di Rochester
- Kanker Payudara42 studi
- Kanker Paru Non-Sel Kecil37 studi
- Kanker Metastatik31 studi
- Kanker (semua jenis)30 studi
- Kanker Ovarium29 studi
- Kanker Kolorektal29 studi
- Mieloma Multipel24 studi
- Gagal Jantung22 studi
- Kanker Prostat22 studi
- Kanker Pankreas22 studi
- Kanker Endometrium20 studi
- Kanker Paru20 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.